In one paragraphArticle in Angewandte Chemie (International ed. in English), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
8 authors.
Yun-Peng WangSchool of Pharmaceutical Sciences, School of Chemistry and Chemical Engineering, Shanghai Key Laboratory for Molecular Engineering of Chiral Drugs, State Key Laboratory of Synergistic Chem-Bio Synthesis, Shanghai Jiao Tong University, Shanghai, China.
Bao-Kuan GuoSchool of Pharmaceutical Sciences, School of Chemistry and Chemical Engineering, Shanghai Key Laboratory for Molecular Engineering of Chiral Drugs, State Key Laboratory of Synergistic Chem-Bio Synthesis, Shanghai Jiao Tong University, Shanghai, China.
Kun FangSchool of Pharmaceutical Sciences, School of Chemistry and Chemical Engineering, Shanghai Key Laboratory for Molecular Engineering of Chiral Drugs, State Key Laboratory of Synergistic Chem-Bio Synthesis, Shanghai Jiao Tong University, Shanghai, China.
Tong-Mei DingSchool of Pharmaceutical Sciences, School of Chemistry and Chemical Engineering, Shanghai Key Laboratory for Molecular Engineering of Chiral Drugs, State Key Laboratory of Synergistic Chem-Bio Synthesis, Shanghai Jiao Tong University, Shanghai, China.ORCID https://orcid.org/0000-0002-2546-961X Shu-Yu ZhangSchool of Pharmaceutical Sciences, School of Chemistry and Chemical Engineering, Shanghai Key Laboratory for Molecular Engineering of Chiral Drugs, State Key Laboratory of Synergistic Chem-Bio Synthesis, Shanghai Jiao Tong University, Shanghai, China.ORCID https://orcid.org/0000-0002-1811-4159 Si-Hua HouSchool of Pharmaceutical Sciences, School of Chemistry and Chemical Engineering, Shanghai Key Laboratory for Molecular Engineering of Chiral Drugs, State Key Laboratory of Synergistic Chem-Bio Synthesis, Shanghai Jiao Tong University, Shanghai, China.ORCID https://orcid.org/0000-0001-7397-8753 Yong-Qiang TuSchool of Pharmaceutical Sciences, School of Chemistry and Chemical Engineering, Shanghai Key Laboratory for Molecular Engineering of Chiral Drugs, State Key Laboratory of Synergistic Chem-Bio Synthesis, Shanghai Jiao Tong University, Shanghai, China.ORCID https://orcid.org/0000-0002-9784-4052 Funding
National Key R&D Program of China 2023YFA1506400National Key R&D Program of China 2023YFA1506401National Key R&D Program of China 2023YFA1506403NSFC 22471160NSFC 92256303NSFC and 22531005Postdoctoral Fellowship Program of CPSF BX20240218Postdoctoral Fellowship Program of CPSF GZC20241025Shanghai Frontiers Science Center of Drug Target Identification and Delivery ZXWH2170101State Key Laboratory of Synergistic Chem-Bio Synthesis sklscbs202543
6 · The paper itselfAbstract
The efficient, single-step construction of angular azatetracyclic frameworks bearing vicinal quaternary stereocenters remains a formidable challenge in synthetic chemistry. Herein, we disclose the first borane-catalyzed cascade reorganization of N-cycloalkylidenyl (CAD)-substituted aryl cycloalkylamines that enables rapid access to these architectures. Initiated by B(C
Indexed as
angular azatetracyclic scaffoldscyclization/dicycloexpansionskeletal reorganizationvicinal quaternary carbon centers
Identifiers
PMID42464709
PMCPMC13528515
What OpenQuestion holds
Textmetadata
Read underepoch 390